Suggested remit: To appraise the clinical and cost effectiveness of burosumab within its marketing authorisation for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia.
Please note that following on from information provided to NICE by the company in September 2022, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- TA
- ID number:
- 3924
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2026 | Discontinued. Please note that following on from information provided to NICE by the company in September 2022, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 September 2022 | Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia ID3924]. For information, the company has advised that they are not in a position to apply for a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme until further notice from the company. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 05 September 2022 | Topic selection |
| 06 May 2022 (14:00) | Scoping workshop |
| 17 March 2022 - 14 April 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 February 2021 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual